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SUMMARY
B lymphocytes have critical roles as positive and negative regulators of immunity. Their inhibitory 
function has so far been associated primarily with interleukin (IL)-10 because B cell-derived IL-10 
can protect against autoimmune disease and increase susceptibility to pathogens1,2. Here, we 
identify IL-35-producing B cells as novel key players in the negative regulation of immunity. 
Mice in which only B cells did not express IL-35 lost their ability to recover from the T cell-
mediated demyelinating autoimmune disease experimental autoimmune encephalomyelitis (EAE). 
In contrast, these mice displayed a strikingly improved resistance to infection with the intracellular 
bacterial pathogen Salmonella typhimurium, as shown by their superior containment of the 
bacterial growth and their prolonged survival both after primary infection, and upon secondary 
challenge after vaccination, compared to control mice. The increased immunity found in mice 
lacking IL-35 production by B cells was associated with a higher activation of macrophages and 
inflammatory T cells, as well as an enhanced stimulatory function of B cells as antigen-presenting 
cells (APC). During Salmonella infection IL-35- and IL-10-producing B cells corresponded to two 
largely distinct sets of surface-IgM+CD138hiTACI+CXCR4+CD1dintTim1int plasma cells 
expressing the transcription factor Blimp1. During EAE CD138+ plasma cells were also the major 
source of B cell-derived IL-35 and IL-10. Collectively, our data unravel the importance of IL-35-
producing B cells in regulation of immunity, and highlight IL-35 production by B cells as a novel 
therapeutic target for autoimmune and infectious diseases. More generally, this study emphasizes 
the central role of activated B cells, particularly plasma cells, and their production of cytokines in 
the regulation of immune responses in health and disease.
RESULTS & DISCUSSION
The inhibitory activities of B cells involve their production of IL-10, which in mice can 
protect from autoimmunity, but impair resistance to infection3-6. Such suppressive function 
could be relevant to human diseases. A defect in IL-10 secretion by B cells was observed in 
patients with multiple sclerosis (MS) and type 1 diabetes7,8. Furthermore, B cell depletion 
therapy had deleterious effects in some patients with MS or ulcerative colitis (UC)9,10. B 
cell depletion also led to UC or psoriasis in patients with Grave’s disease, or rheumatoid 
arthritis, respectively11,12. These effects were probably not all due to a loss of IL-10-
producing B cells. Mouse B cells could inhibit immunity independently of IL-1013,14. 
However no other mediator to account for this has been characterized. There is an urgent 
need to identify additional factors mediating the regulatory functions of B cells.
B cells require activation to exert suppressive activity, and Toll-like receptors (TLR) are 
critical in this process. In particular, mice with deficiencies in both TLR2 and TLR4 
restricted to B cells developed a chronic EAE after immunization with the encephalitogenic 
peptide from myelin oligodendrocyte glycoprotein (MOG35-55), while control mice 
recovered from disease15. Using mice with single deficiencies in these TLR restricted to B 
cells (B-TLR2−/− and B-TLR4−/− mice, respectively), we found that TLR4 was the most 
critical for B cell-mediated suppression in EAE (Fig. 1a and Extended Data Fig. 1a). 
Together with previous studies3, these results establish TLR4 and CD40 as receptors 
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essential for the regulatory function of B cells in EAE. CD40 also contributes to the 
protective roles of B cells in UC, and collagen-induced arthritis4,5.
IL-10 production by B cells is required for recovery from EAE3. Naïve B cells produced 
IL-10 after TLR4 engagement, but not upon co-stimulation via TLR4+CD40 (Fig. 1b and 
Extended Data Fig. 1b). To assess whether B cells could express a distinct suppressive 
factor upon TLR4+CD40 stimulation, we performed Affymetrix array analyses on (i) naïve 
B cells, (ii) B cells activated via TLR4, and (iii) B cells activated via TLR4+CD40, and 
focused on genes coding for secreted molecules (Extended Data Fig. 1c). Among the genes 
differentially expressed, of particular interest was Epstein-Barr virus-induced gene 3 (EBi3), 
a member of the IL-12 cytokine family that can dimerize with p28 or p35 to generate IL-27 
or IL-35, respectively, which both have suppressive functions16-19. B cells did not express 
p40 mRNA, highlighting its cell-type specific expression pattern20, but constitutively 
transcribed p35 (Extended Data Fig. 1d). In fact, B cells were the major source of p35 
mRNA in secondary lymphoid tissues (Fig. 1d). B cells up-regulated expression of p35 and 
EBi3 mRNA, as well as EBi3 protein upon activation via TLR4+CD40, which was further 
increased upon BCR engagement, suggesting they could secrete IL-35 (Fig. 1e and 
Extended Data Fig. 1). This was confirmed by co-immunoprecipitation on supernatants from 
TLR4+CD40-activated B cells (Fig. 1f). We conclude that B cells can secrete IL-35 after 
activation via TLR4+CD40.
To evaluate the role of IL-35 expression by B cells during EAE, we used mice with B cell-
restricted deficiency in p35 (B-p35−/−), or EBi3 (B-EBi3−/−), or control mice with wild-type 
B cells (B-WT). We also used mice in which B cells could not express p40 (B-p40−/−), or 
p28 (B-p28−/−), because p35 can dimerize with p40 to form IL-12, and EBi3 can associate 
with p28 to form IL-27. B cells secreted p28 after activation (Extended Data Fig. 1j). After 
immunization with MOG35-55, B-p35−/− and B-EBi3−/− mice developed exacerbated forms 
of EAE, while B-p40−/− and B-p28−/− mice had disease courses similar to B-WT controls 
(Fig. 2a and Extended Data Fig. 2). Therefore, B cells limited EAE pathogenesis through 
provision of IL-35. EAE pathogenesis involves TH1 and TH17 cells, which express IFN-γ 
and IL-17, respectively21,22. B-p35−/− mice displayed increased MOG-reactive IFN-γ and 
IL-17 production compared to control mice (Fig. 2b and Extended Data Fig. 2d). In contrast, 
B-p28−/− and B-p40−/− mice mounted normal T cell responses (Fig. 2b and Extended Data 
Fig. 2). B-p35−/− mice had more CD4+ T cells and mononuclear phagocytes in central 
nervous system than B-WT mice (Extended Data Fig. 2), suggesting that B cell-derived 
IL-35 limited disease by reducing the accumulation of pathogenic cells in the target organ. 
These data demonstrate that B cell-derived IL-35 is a critical regulator of T cell-mediated 
autoimmunity.
The mechanisms underlying the suppressive activities of IL-35 remain poorly understood23. 
During EAE, the increased T cell response observed in B-p35−/− mice was not due to a 
defect in CD4+Foxp3+ T regulatory (Treg) cells (Extended Data Fig. 2), which are 
protective in this disease24. B cells from B-p35−/− mice expressed higher levels of activation 
markers (CD44, CD69), and molecules involved in antigen presentation to CD4+ T cells 
(MHC-II, CD80, CD86) compared to control B cells (Extended Data Fig. 3). Accordingly, 
they were more potent APC than control B cells, stimulating higher proliferation and 
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production of inflammatory cytokines (IL-17 and GM-CSF) by MOG-reactive CD4+ T cells 
(Fig. 2c, d and Extended Data Fig. 3c). Preliminary studies showed that B-p35−/− mice were 
susceptible to EAE induced with human MOG, a disease dependent on the pathogenic 
functions of B cells25. These findings introduce IL-35 as a regulator of the APC capacity of 
B cells.
To test the role of B cell-derived IL-35 in infection, we challenged B-p35−/−, B-EBi3−/−, and 
B-p40−/− mice with the Gram-negative bacterium Salmonella typhimurium. This 
intracellular pathogen causes a disease in mice that resembles typhoid fever in humans, 
which is responsible for approximately 20 million cases and 600,000 deaths annually26. B-
p35−/− and B-EBi3−/− mice displayed prolonged survival compared to B-p40−/− and B-WT 
mice, both after primary infection, and upon secondary challenge (Fig. 3a). This improved 
resistance correlated with better control of the bacterial burden in spleen and liver, increased 
accumulation of macrophages in these organs, and stronger inflammatory T cell responses 
towards the pathogen (Fig. 3b, c and Extended Data Fig. 4). In contrast, B cell-derived IL-35 
had no effect on Treg frequencies, global frequencies of activated T cells, or humoral 
immunity against Salmonella (Extended Data Fig. 4 and 5a). B-p35−/− mice also mounted 
normal antibody responses against a hapten-protein antigen (Extended Data Fig. 5b). 
Consistent with the role of CD40 in IL-35 production by B cells (Fig. 1), mice with a B cell-
restricted deficiency in CD40 displayed enhanced control of Salmonella infection (Extended 
Data Fig. 5c). These data demonstrate that B cells can inhibit anti-microbial immunity 
through production of IL-35.
B cells can also inhibit anti-Salmonella immunity through provision of IL-106. To identify 
IL-10- and IL-35-producing B cells, and to clarify their relationship, we quantified EBi3 and 
IL-10 mRNA in CD19+CD138− B cells and CD138hi plasma cells during Salmonella 
infection (Fig. 4a and Extended Data Fig. 6). EBi3 and IL-10 were exclusively induced in 
CD138hi cells (Fig. 4a). Single cell PCR analyses indicated that distinct sets of CD138hi 
cells expressed the mRNA for IL-10 or for both IL-35 subunits EBi3 and p35 (Fig. 4b). We 
therefore characterized further these plasma cells. They expressed uniform surface levels of 
IgM, CD80, CD86, MHC-II, CD40, CD69, CD44, CD43, TACI, and CXCR4, as well as 
intermediate levels of CD1d and Tim1 (Extended Data Fig. 6a and d), yet three subsets 
could be distinguished according to CD138 and CD22 levels: CD138intCD22+, 
CD138hiCD22+, and CD138hiCD22− cells (Extended Data Fig. 7). These subsets differed by 
their capacity to produce antibodies, and expressed distinct amounts of mRNA for the 
transcription factors driving plasma cell development (Blimp1, IRF4), or maintaining B cell 
identity (Pax5) (Extended Data Fig. 7), demonstrating that they corresponded to different 
stages of plasma cell development. The expression levels of IL-10 and EBi3 mRNA in these 
subsets correlated with their degree of maturity, and were highest in the most differentiated 
CD138hiCD22− cells (Extended Data Fig. 7c). CD138hiCD22− plasma cells were mostly 
located at the interface between red and white pulp in spleen, in clusters also containing T 
cells, CD11b+ and CD169+ myeloid cells (Extended Data Fig. 7d). Single cell PCR analyses 
revealed that about 6-10% of CD138hi cells expressed IL-10 mRNA, and a similar 
frequency made both IL-35 subunits mRNA, whereas only few cells co-expressed these 
three transcripts (Fig. 4b). Nearly all CD138hi cells transcribing IL-10 or both IL-35 
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subunits co-expressed Blimp1 (Fig. 4c), as expected for plasma cells. The less mature 
CD138intCD22+ population contained little IL-10 or EBi3 mRNA (Extended Data Fig. 7c), 
and only rare cells contained IL-10 mRNA (Fig. 4b), suggesting that expression of IL-10 
and both IL-35 subunits were acquired during plasma cell maturation. These data indicate 
that distinct sets of plasma cells provide IL-10 and IL-35 during Salmonella infection.
To study further cytokine production by plasma cells, we isolated CD138hi and 
CD19+CD138− B cells from mice infected with Salmonella, and re-stimulated them ex vivo. 
Plasma cells consistently secreted more IL-10 than B cells (Fig. 4d and Extended Data Fig. 
8). Around 70% of CD138hi plasma cells up-regulated IL-10 expression after stimulation 
with phorbol 12-myristate 13-acetate plus ionomycin, a classical treatment for identifying 
cytokine-producing cells (Extended Data Fig. 8). CD138+ plasma cells were also the major 
B cell subtype expressing the proteins EBi3 and p35 that compose IL-35 compared to 
CD19+CD138− B cells (Fig. 4e). In contrast, CD138hi plasma cells did not secrete IL-6, a 
mediator of the pro-inflammatory functions of B cells27, unlike CD19+CD138− B cells 
(Extended Data Fig. 8). This lack of IL-6 production, which may be due to a repressive 
effect of Blimp128 distinguishes IL-10- and IL-35-expressing plasma cells from IL-10-
producing CD1dhi B cells (Extended Data Fig. 8). These data demonstrate that CD138hi 
plasma cells have a remarkable propensity to express anti-inflammatory cytokines but not 
IL-6 during Salmonella infection. Our results emphasize the regulatory potential of plasma 
cells compared to other B cell subsets.
Our study demonstrates that B cells can produce IL-35, and identifies IL-35-producing B 
cells as novel critical regulators of immunity. At a time window during Salmonella infection 
when both B cell-derived IL-106 and IL-35 exerted suppressive functions, plasma cells were 
the major B cell type expressing these cytokines. Plasma cells were also the major B cell 
subset expressing IL-10 and IL-35 subunits during EAE (Extended Data Fig. 9). During 
Salmonella infection, IL-10 and IL-35 were made by distinct sets of plasma cells, suggesting 
that these two suppressive axes can operate in parallel. In line with this, mice in which 
individual B cells could express either IL-10, or IL-35, but not both cytokines, displayed a 
normal EAE course (Extended Data Fig. 9). Accordingly, B and plasma cells could produce 
IL-10 without concomitant IL-35 secretion (Extended Data Fig. 9). Future studies shall 
assess whether “regulatory plasma cells” producing IL-10 and IL-35 (but not IL-6) can 
provide novel opportunities for immune intervention.
Methods
Mice, immunization and infection
C57BL/6, TLR2−/−, TLR4−/−, EBi3−/−, p28−/−, p35−/−, p40−/−, CD40−/−, IL-10−/−, 
IL-10−/−p35−/−, p35−/− EBi3−/−p40−/−, JHT, IL-10.eGFP6, and p35−/−IL10.eGFP mice were 
bred under specific pathogen-free conditions. B-TLR2−/−, B-TLR4−/−, B-p28−/−, B-p35−/−, 
B-EBi3−/−, B-p40−/−, B-CD40−/−, B-IL-10−/−, and B-IL-10−/−p35−/− mice were obtained by 
a previously described mixed bone marrow chimera approach using lethally irradiated 
C57BL/6 or JHT mice as recipients3,6. Briefly, B-p35−/− mice were obtained by 
reconstituting recipient mice with a mixture of bone marrow cells from B cell-deficient JHT 
mice (80%) and p35-deficient mice (20%). Control B-WT chimera were obtained using a 
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mixture of bone marrow cells from JHT mice (80%) and C57BL/6 mice (20%) for 
experiments shown in Fig. 1a, Fig. 2a left panel, and Fig. 2a right panel. For all other 
experiments (including Fig. 2a middle panel, and Extended Data Fig. 2a), corresponding B-
WT control chimera were obtained as outlined in Extended Data Fig. 10, by reconstituting 
irradiated mice with a mixture of bone marrow cells from C57BL/6 mice (80%) and from 
mice deficient in the gene of interest (20%). The various control chimera are indistinctly 
called “corresponding B-WT mice” throughout the study. EAE was induced by 
immunization with MOG35-55 peptide, or recombinant human MOG extracellular domain 
emulsified in Complete Freund’s adjuvant (Sigma-Aldrich) and pertussis toxin (Sigma-
Aldrich), and assessed as previously described3. Mice with a weight loss >20% were 
humanely euthanized according to ethical regulations. To measure the MOG-reactive T cell 
response, 8×105 splenocytes were stimulated in flat-bottomed 96-well plates with different 
concentrations of MOG35-55 peptide for 2 days, and culture supernatants were then analyzed 
by ELISA to determine concentrations of IFN-γ and IL-17 (coating/detection with clones 
R4-6A2 and XMG1.2 for IFN-γ, and TC11-18H10 and TC11-8H4 for IL-17). Mice were 
infected intravenously with 100 colony-forming units (CFU) Salmonella typhimurium strain 
SL1344, and 106 or 107 CFU attenuated Salmonella typhimurium strain SL7207, and 
assessed as previously described, including for histological analyses6. All experiments were 
reviewed and approved by appropriate institutional review committees (University of 
Edinburgh ethical review committee, Comite d’Ethique Midi-Pyrenees, and LAGeSo 
Berlin), and were conducted in accordance with U.K., French, and German legislations, in 
compliance with European community council directive 68/609/EEC guidelines. Mice were 
of C57BL/6 strain, 6-12 weeks old at start of experiments, and of male and female genders. 
EAE experiments, and Salmonella infections were performed in a blinded manner, and 
identities of the mice were revealed upon termination of the experiment. No randomization 
was used. Estimation of size groups was based on our previous experience with these 
disease models, without a priori determination via power calculation.
B cell purification and activation
B cells were obtained by magnetic isolation using negative selection with αCD11b, 
αCD11c, and αCD43 microbeads (Miltenyi Biotec). B cells (>99% pure) were activated as 
previously described15 at 5×105 cells/well in 96-well flat-bottom plates with LPS 
(Escherichia coli serotype 055:B5; Sigma-Aldrich), CpG-ODN-1826 (TIB MolBiol, 
Germany), PGN (Streptomyces species 79682; Sigma-Aldrich), agonistic αCD40 antibody 
(clone FGK-45, produced in house), mouse CD40L-expressing L47 cells (L47-CD40L+), or 
control L5 cells (L5-ctrl) as indicated. Culture supernatants were harvested at 72 h, and 
IL-10 concentrations measured by Bio-Plex (Bio-Rad, USA). For the microarray 
experiments, B cells purified as described above were further depleted of possible 
contaminants by another round of magnetic negative selection after re-labelling with 
αCD11b, αCD11c, αCD43, αCD90, and αDX5 microbeads (Miltenyi Biotec). B cells were 
activated with LPS (1μg/ml) or LPS (1μg/ml) + αCD40 (10 μg/ml). Dead cells were 
eliminated from the 24 h and 72 h activated culture by labelling with propidium iodide (PI), 
and sorting on FACS Diva (BD Biosciences). Cells were lysed in RLT buffer (Qiagen), and 
total RNA was extracted using RNeasy Mini Kit (Qiagen).
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Gene array hybridization and data analysis
cRNA were hybridized on Affymetrix MG 430 2.0 arrays, using standard Affymetrix 
protocol after quality control with Agilent 2100 Bioanalyzer and quantification with 
NanoDrop ND-1000 spectrophotometer, as previously described29. The significantly 
differentially regulated genes were detected using a t-test based R-script, with p values 
adjusted using Benjamini Hochberg procedure. In order to be selected in a comparison of 
two conditions, each Affy IDs had to fulfill the following criteria: (i) be present in at least 
three of the four arrays for at least one of the two conditions compared, (ii) to have a mean 
signal intensity higher than 50 in at least one of the two conditions, and (iii) to show an 
adjusted p-value <0.01 (t-test) in the comparison of the two conditions. The genes 
differentially expressed between TLR4- and TLR4+CD40-activated B cells (t-test; p<0.01), 
and differentially modulated during B cell activation (t-test; p<0.01), were then selected and 
filtered using the gene ontology resource (www.geneontology.org) to focus on secreted 
molecules (Extended Data Fig. 1c). Seven genes fulfilled these criteria, among which five 
were uniquely increased in TLR4+CD40-stimulated B cells (Extended Data Fig. 1c). 
Hierarchical clustering was performed with the MeV program (version 4.8.1)30 using 
Pearson correlation and average Linkage.
Analysis of mRNA expression by B and plasma cells
Sorted B and plasma cells were lysed in Trizol, and RNA was prepared (AMS 
Biotechnology). After DNase treatment (Ambion), RNA was reverse-transcribed with a 
Reverse Transcription System (Promega). Quantitative RT-PCR was performed on an 
MX3005P QPCR System (Stratagene), with LightCycler FastStart DNA Master SYBR 
Green I (Roche). Transcripts were quantified using β-actin as standard, and the following 
forward (FP) and reverse (RP) primers (MWG Biotech): β-actin FP: 5′-
TGGAATCCTGTGGCATCCATGAAAC-3′, β-actin RP: 5′-
TAAAACGCAGCTCAGTAACAGTCC-3‘; EBi3 FP: 5‘-
CGGTGCCCTACATGCTAAAT-3′, EBi3 RP: 5′- GCGGAGTCGGTACTTGAGAG-3′; 
p35 FP: 5′-CATCGATGAGCTGATGCAGT-3′, p35 RP: 5′-
CAGATAGCCCATCACCCTGT-3′; IL-10 FP: 5′-AGC CGG GAA GAC AAT AAC 
TG-3′, IL-10 RP: 5′-CAT TTC CGA TAA GGC TTG G-3′; Blimp1 FP: 5′- GGC ATT CTT 
GGG AAC TGT GT-3′; Blimp1 RP: 5′- GAC AGA GGC CGA GTT TGA AG-3′; IRF4 FP: 
5′- GCAGCTCACTTTGGATGACA-3′; IRF4 RP: 5′- CCAAACGTCACAGGACATTG-3′; 
Pax5 FP: 5′- AACTTGCCCATCAAGGTGTC-3′; Pax5 RP: 5′- 
CTGATCTCCCAGGCAAACAT-3′.
Western blot and immunoprecipitation
Activated B cells were treated with GolgiStop (BD Biosciences, Germany) to block protein 
secretion during the last 4 h of stimulation. B cells (2×107) were lysed with 500 μl RIPA 
buffer (Thermo Fisher Scientific, USA) supplemented with protease inhibitors (Thermo 
Fisher Scientific, USA). Cells isolated from mice infected with Salmonella were directly 
lysed in RIPA buffer containing protease inhibitors. Protein concentrations of lysates were 
determined using the BCA Protein Assay Kit (Thermo Fisher Scientific, USA). Proteins 
were separated on a polyacrylamide gel and transferred to a PVDF membrane (Bio-Rad 
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Laboratories, USA) using semi-dry blotting. EBi3, p35, and actin were detected using rabbit 
anti-EBi3 (M-75 polyclonal IgG, Santa Cruz Biotechnology, USA), rabbit anti-p35 
(EPR5736 polyclonal IgG, Abcam, UK), or rabbit anti-actin (I-19 polyclonal Ab, Santa Cruz 
Biotechnology, USA) primary antibody, and horseradish peroxidase (HRP)-conjugated 
secondary anti-rabbit antibody (cat. number: 81-6120, Invitrogen, USA; or cat. number: 
111-035-144, Jackson ImmunoResearch, USA) with ECL (GE Healthcare, UK) as HRP 
substrate. The chemiluminescence signal was measured using the Image-Reader LAS-3000 
(Fujifilm, Japan). For immunoprecipitation supernatant from B cells activated with LPS
+αCD40 (clone FGK-45, 10 μg/ml) were incubated overnight at 4°C with 2 μg/ml anti-p35 
(C18.2, eBioscience). Immunoprecipitation was performed using μMACS Protein G 
Microbeads (Miltenyi Biotech), followed by immunoblot to detect EBi3.
B -T cell co-cultures
The protocol for B-T cell co-cultures was adapted from a previous report25. Briefly, B cells 
were magnetically sorted from pooled spleens and LN of B-p35−/− or B-WT mice on day 10 
post-EAE induction as CD19+ cells (~98% pure), and Teff cells were FACS-sorted from the 
CD19-depleted fraction as previously described31. 50×104 B cells and 1×104 CD4+CD25− T 
cells (Teff) were then co-cultured in the indicated combinations in presence of increasing 
concentrations of MOG35-55. After 48 h cultures received 1μCi 3H-thymidine, and 3H-
thymidine incorporation was measured 16 h later with a Top-Count NXT liquid scintillation 
counter (Perkin Elmer). Before addition of 3H-thymidine, samples of culture supernatants 
were collected to quantify concentrations of IL-17, IFN-γ, GM-CSF and IL-6 using Bio-Plex 
(Bio-Rad).
Plasma cell purification
Plasma cells and B cells were obtained from C57BL/6, p35−/−, p35−/−EBi3−/−p40−/−, 
IL-10.eGFP, and p35−/−IL-10.eGFP mice on day 3 after infection with 107 CFU Salmonella 
(SL7207) by magnetic isolation using αCD138-PE (clone 281-2, BD Pharmingen) and α-PE 
microbeads (Miltenyi Biotec). The negative fraction was then subjected to FACS sorting to 
obtain high purity CD19+CD138− B cells. The positive fraction was then stained for CD22 
(clone OX-97, Biolegend), and subjected to FACS sorting to obtain high purity plasma cells 
(CD138hi), and plasma cell subsets (CD138intCD22+, CD138hiCD22+, and CD138hiCD22− 
cells). For Western blot, CD138hi and CD138int cells were isolated as CD138+ plasma cells 
from infected mice by magnetic isolation using αCD138-PE (clone 281-2, BD Pharmingen) 
and α-PE microbeads (Miltenyi Biotec).
Single Cell PCR analysis
Single cells were sorted on a FACS Aria II (BD Biosciences) into a 96-well PCR plate, 
immediately frozen in liquid nitrogen and stored at −80°C until further use. For detection of 
respective transcripts a two-step PCR approach was used. Reverse transcription and the first 
PCR step were carried out in a one-step reaction using the QIAGEN OneStep RT-PCR kit 
according to the manufacturer’s instructions. As recommended in these instructions, specific 
nested primers (MWG Biotech) were used as follows: EBi3nested FP: 5‘-
CCTTCATTGCCACTTACAGG-3′, EBi3nested RP: 5′- 
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TAATCTGTGAGGTCCTGAGC-3′; p35nested FP: 5′- 
CATTCTAGACAAGGGCATGC-3′, p35nested RP: 5′-
GTGATGGGAGAACAGATTCC-3′; IL-10nested FP: 5′- 
TCTTACTGACTGGCATGAGG-3′; IL-10nested RP: 5′- 
CTTCTACCAGGTAAAACTGG-3′; Blimp1nested FP: 5′-
CGTGAAGTTTCAAGGACTGG-3′; Blimp1nested RP: 5′- 
GTGGTGGAACTCCTCTCTGG-3′. For validation of sorting β-actin primers were added to 
the reaction mixture. After this first reaction, an aliquot of the PCR product was loaded on 
an agarose gel, and only β-actin positive samples were considered to further analysis. A 100-
fold dilution of the PCR product was subsequently used as template for the second PCR 
reaction using the primers described in the section “Analysis of mRNA expression by B and 
plasma cells”. Amplification of the respective transcript was verified on an agarose gel.
Additional reagents
Antibodies used in this study also included anti-Ly6C (clone AL21, cat number 557359, BD 
Pharmingen), anti-IFN-γ (clone XMG1.2, BD Pharmingen), anti-CD154 (cat number 
130-092-105, Miltenyi Biotech), anti-CD62L (MEL14, in house).
Statistics
Statistical analysis was performed using GraphPad Prism (version 5.02 for Windows, 
GraphPad Software, USA). EAE data distribution did not differ from normal distribution, as 
evaluated using Kolmogorov-Smirnov test. Equality of variances between groups was 
assessed before analyses by ANOVA or t-test. Groups were compared using ANOVA, two-
tailed t-test, or Wilcoxon test, as indicated in figure legends. t-test were modified using 
Welch’s correction in case of unequal variance. One-way and Two-way ANOVA were 
followed by Bonferroni post-test. No samples were excluded from analysis. Statistical 
analysis of the gene array data is described in “Gene array hybridization and data analysis”.
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Extended Data
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Figure 1. B cells secrete IL-35 upon activation via TLR4 and CD40
a, EAE was induced in B-TLR2−/− (grey squares; n=8), B-TLR4−/− (black triangles; n=8), 
and B-WT mice (grey circles; n=16) by immunization with MOG35-55 peptide in complete 
Freund’s adjuvant. Data show clinical EAE scores from two independent experiments (mean 
± SEM). Cumulative disease scores were compared using unpaired t-test. b, Splenic B cells 
from IL-10.eGFP mice were stimulated for 72 h with LPS (1 μg/ml) or LPS (1 μg/ml)
+αCD40 (10 μg/ml), and eGFP expression was measured by flow cytometry. Plots show 
eGFP expression by live CD19+ cells. Results are representative of three independent 
experiments. c, Hierarchical cluster analysis of secreted factors differentially expressed 
between B cells activated with LPS or LPS+αCD40 (Pearson correlation with average 
linkage). Affymetrix microarrays were performed in quadruplicates from splenic naïve B 
cells, and from B cells activated with LPS (1 μg/ml) or LPS (1 μg/ml)+αCD40 (10 μg/ml) 
for 24 h and 72 h. Expression levels of each gene is shown for each array compared to its 
average value for the 20 arrays, with a scale ranging from two-fold increase (yellow) to two-
fold decrease (blue) compared to average. d, p35 mRNA expression was quantified by real-
time PCR in LN and spleen from naïve C57BL/6 and B cell-deficient JHT mice, as well as 
in B cells purified from LN and spleen of C57BL/6 mice. Data show the compilation of 
three independent experiments (mean ± SEM). e, Splenic B cells were activated as indicated 
for 72 h, and treated with GolgiStop for the last 4 h of culture. B cell lysates were separated 
on SDS-PAGE gel and blotted with anti-EBi3 or anti-actin antibody. Data show 
representative result from three independent experiments. f, B cells from C57BL/6 or p35-
deficient mice were activated for 72 h with LPS+αCD40 (clone FGK-45; 10 μg/ml). Culture 
supernatants were subjected to immunoprecipitation with anti-p35 followed by Western blot 
with anti-EBi3 antibody. Data shown are representative of two independent experiments.
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Figure 2. IL-35 expression by B cells is required for recovery from EAE
a, EAE was induced in: left panel: B-p35−/− (grey squares; n=17) and B-WT mice (black 
circles; n=16), middle panel: B-EBi3−/− (grey squares, n=9) and corresponding B-WT mice 
(black circles; n=5), right panel: B-p40−/− (grey squares; n=10) and B-WT mice (black 
circles; n=16) by immunization with MOG35-55 peptide in Complete Freund’s adjuvant. 
Data show clinical EAE scores from two independent experiments (mean ± SEM). 
Cumulative disease scores were compared using unpaired t-test. b, Splenocytes were 
harvested from mice on day 10 after EAE induction, and pooled before re-stimulation for 48 
Shen et al. Page 23
Nature. Author manuscript; available in PMC 2014 December 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
h with MOG35-55 in increasing concentrations. Culture supernatants were analyzed by 
ELISA to determine IFN-γ and IL-17 concentrations. Data show representative result from 
two independent experiments. c, EAE was induced in B-p35−/− and corresponding B-WT 
mice by immunization with MOG35-55 peptide in Complete Freund’s adjuvant. B cells and 
CD4+CD25− T cells (Teff) were isolated from pooled draining LN and spleens on day 10 
after immunization. 5×105 B cells from B-p35−/− or B-WT mice were then cultured with 
1×104 Teff cells from B-p35−/− or B-WT mice in presence of MOG35-55 in increasing 
concentrations, as indicated. Proliferation was assessed after 64 h by 3H-thymidine 
incorporation. CPM: counts per minute. Data show representative results from two 
independent experiments. d, Supernatants from cultures as described in (c) were harvested 
after 48 h, and analyzed by Bio-Plex to determine the concentrations of IL-17 and GM-CSF. 
Data shown (mean ± SEM) are pooled from two independent experiments. b-d, Graphs 
show mean ± SEM. Results were compared using a Two-way ANOVA followed by a 
Bonferroni post-test (* p<0.05, ** p<0.01; *** p<0.001).
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Figure 3. B cell-derived IL-35 enhances susceptibility to Salmonella typhimurium
a, Top panel shows survival curves of B-p35−/− (n=14) and their corresponding B-WT mice 
(n=16), B-EBi3−/− (n=12) and their corresponding B-WT mice (n=13), B-p40−/− (n=13) and 
their corresponding control B-WT mice (n=14) after i.v. infection with 100 colony-forming 
units (CFU) virulent Salmonella typhimurium strain (SL1344). Data are pooled from two 
independent experiments for each panel. Survival curves were compared using the Wilcoxon 
test. The bottom panel shows survival curves of B-p35−/− (n=15) and their corresponding B-
WT mice (n=16), B-EBi3−/− (n=15) and their corresponding B-WT mice (n=15), B-p40−/− 
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(n=11) and their corresponding control B-WT mice (n=14), which were vaccinated with 
attenuated Salmonella (SL7207) and 90 days later re-challenged with 100 CFU virulent 
Salmonella (SL1344). Data are pooled from two independent experiments. Survival curves 
were compared using the Wilcoxon test. b, (left panel) representative FACS plot of 
mononuclear phagocytes (MP) gated as CD11b+Ly6Chi cells among live splenocytes from a 
B-WT mouse at day 6 p.i. with SL1344; (right panel) frequencies of MP per spleen at day 6 
p.i. in B-p35−/−, B-EBi3−/−, and B-p40−/− mice together with their corresponding control B-
WT mice. Numbers of mice analyzed: B-p35−/− (n=6) and their corresponding B-WT mice 
(n=8), B-EBi3−/− (n=7) and their corresponding B-WT mice (n=5), B-p40−/− (n=8) and their 
corresponding control B-WT mice (n=8). Data are pooled from two independent 
experiments. Graphs show mean ± SEM. Data were analyzed with unpaired t-test. p-values 
> 0.05 are considered as non significant (ns). c, Indicated groups of mice were infected with 
attenuated Salmonella (SL7207). After 21 days cells from bone marrow were stained for 
surface CD4 and intracellular CD40L or IFN-γ after 6 h re-stimulation with heat-killed 
Salmonella. The left panel shows representative FACS plots of IFN-γ+ cells among CD4+ T 
cells from B-WT and B-p35−/− mice. Middle and right panels show, respectively, 
frequencies of IFN-γ+ and CD40L+ cells among CD4+ T cells. Data shown are pooled from 
two independent experiments with the following total number of mice: B-p35−/− (n=12) and 
their corresponding B-WT mice (n=10), B-EBi3−/− (n=8) and their corresponding B-WT 
mice (n=9), B-p40−/− (n=15) and their corresponding control B-WT mice (n=9). Graphs 
show mean ± SEM. Data were analyzed with an unpaired t-test.
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Figure 4. IL-10 and IL-35 are expressed by CD138hi plasma cells during Salmonella 
typhimurium infection
a, Splenic plasma cells (CD138hi) and B cells (CD19+CD138−) were isolated from C57BL/6 
mice on days 0, 1, 3, 5, and 8 after infection with 107 CFU attenuated Salmonella (SL7207). 
EBi3 and IL-10 mRNA expression were then quantified by real-time PCR. Data show fold 
induction of EBi3 (left) and IL-10 (right) mRNA expression in plasma and B cells during 
infection compared to naïve B cells. A compilation of five independent experiments is 
shown (mean ± SEM). b, Single cells of CD138intCD22+, CD138hiCD22+, and 
CD138hiCD22− plasma cells were sorted by FACS from C57BL/6 mice on day 3 after 
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infection with 107 CFU attenuated Salmonella (SL7207). A total of 208 CD138intCD22+, 
206 CD138hiCD22+, and 189 CD138+CD22− single cells gave a positive signal for β-actin, 
and were included in data shown. Data show percentages of IL-10+ (left), p35+EBi3+ 
(middle), and IL-10+p35+EBi3+ (right) cells among each subset. c, Blimp1 mRNA 
expression in those single cells analyzed in (c) were also detected by single-cell PCR. Data 
show the percentages of Blimp1+ cells among IL-10-expressing (left), as well as p35 and 
EBi3 co-expressing cells (right). d, CD138hi plasma cells and CD19+CD138− B cells were 
isolated from spleen of C57BL/6 mice on day 3 after infection with attenuated Salmonella 
(SL7207; 107 CFU) using a combination of magnetic and FACS methods. Naïve B splenic 
B cells were isolated from unchallenged C57BL/6 mice by magnetic selection. Isolated cells 
were activated for 24 h with PMA+ionomycin, and IL-10 concentrations in culture 
supernatants were determined by Bio-Plex. Data shown are pooled from 5 independent 
experiments. Results were compared suing unpaired t-test. d, Splenic CD19+CD138− B cells 
(B cells) and CD138+ plasma cells (PC) were isolated from spleens of C57BL/6 (WT) and 
p35−/−EBi3−/−p40−/− (KO) mice on day 3 p.i. with attenuated Salmonella (SL7207; 107 
CFU). B cell lysates were separated on SDS-PAGE gel and blotted with anti-EBi3, anti-p35, 
or anti-actin antibodies. Data show results from two independent cell preparations for WT 
samples, and one preparation for p35−/−EBi3−/−p40−/− B and plasma cells.
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